Latest studies
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
This study is looking at a new medicine called Rocatinlimab for adults with moderate to severe eczema. We want to see if it helps improve skin, reduce itching, and is safe over 24 weeks compared to a dummy medicine.
Atopic DermatitisEstonia - Active not recruitingPHASE3
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
This study is testing a new combination treatment for advanced bowel cancer. It compares a new medicine (S95005) with an existing one (capecitabine), both given with bevacizumab. The aim is to see if the new combination works better for patients who can't have intensive chemotherapy.
Metastatic Colorectal CancerEstonia - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
Crohn's DiseaseEstonia - Active not recruiting
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
This study looks at how well a medicine called Humira works and how safe it is for children aged 6 to 17 with Crohn's disease. It also compares Humira to other common treatments like azathioprine, 6-mercaptopurine, or methotrexate, watching patients over a long time.
Crohn's DiseaseEstonia - Active not recruitingPHASE3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
This study is looking at a new medicine called remibrutinib for people with relapsing multiple sclerosis (RMS). It compares remibrutinib to an existing medicine, teriflunomide, to see how well it works and if it's safe. It's a large study, involving about 800 people.
Relapsing Multiple SclerosisEstonia - RecruitingPHASE3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
This study looks at a new treatment called dostarlimab for certain types of colon cancer that haven't spread. It compares dostarlimab with standard treatments to see if it works better before and after surgery to help patients.
Colonic NeoplasmsNeoplasms, ColonEstonia - RecruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic NeoplasmsEstonia - Active not recruitingPHASE3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
This study looks at a new tablet treatment, upadacitinib, for adults with moderate to severe lupus. It checks how safe and effective the medicine is and aims to reduce symptoms. Some people will get the active drug, others a dummy pill.
Systemic Lupus ErythematosusEstonia - RecruitingPHASE2
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
This study looks at new medications for adults with moderate to severe Crohn's disease. Researchers want to see how well these 'targeted therapies' work and if they cause side effects, to find better ways to manage the condition.
Crohn's DiseaseEstonia - Active not recruitingPHASE3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This study looks at the everyday safety and how well a drug called tolebrutinib is tolerated over a long time. It's for adults with different types of multiple sclerosis (MS) who have already been in earlier tolebrutinib studies.
Relapsing Multiple SclerosisSecondary Progressive Multiple SclerosisProgressive Relapsing Multiple SclerosisEstonia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
This study is looking into a new medicine, Zasocitinib, for people with psoriatic arthritis. It's checking its long-term safety and how well it helps their symptoms. Participants will either get Zasocitinib or a dummy medicine.
Psoriatic ArthritisEstonia - AuthorisedTherapeutic confirmatory (Phase III)
DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.
This study looks at a new drug, obrixtamig, alongside usual treatment for extensive small cell lung cancer. It aims to see if this new combination helps people live longer and feel better compared to the usual treatment alone.
small cell lung cancerEstonia - RecruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
Atherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseEstonia - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
This study looks at the long-term safety and effectiveness of a medicine called Upadacitinib for people with ulcerative colitis. It's for those who haven't fully responded to previous treatment or have completed an earlier study.
Ulcerative Colitis (UC)Estonia - Active not recruitingPHASE3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
This study is for men with cancer who are already taking darolutamide in another Bayer study and are doing well. It lets them keep taking the same medicine at the same dose, continuing their treatment journey under medical supervision.
CancerEstonia - Active not recruitingPHASE3
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
This study is looking at a new medicine called nemolizumab for people with moderate to severe eczema. It aims to understand how safe and effective the medicine is over a long period. Participants would have been in a previous nemolizumab study.
Moderate-to-Severe Atopic DermatitisEstonia - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study looks at new ways to treat ulcerative colitis, a condition causing gut inflammation. We're testing a combination of medicines (JNJ-78934804) for people whose current treatments aren't working well. The goal is to see if these new approaches are safe and effective.
Colitis, UlcerativeEstonia - Active not recruitingPHASE3
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
This study is looking at a specific shingles vaccine in older adults. It wants to see how well the vaccine continues to protect against shingles for many years, how strong the body's immune response remains, and if it's still safe over a long time.
Herpes ZosterEstonia - Enrolling by invitation
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
This study looks at how well Esperoct® works and if it has side effects for men and boys with haemophilia A. Participants will receive their usual treatment and share information about their health over several years.
Haemophilia AEstonia - Active not recruitingPHASE3
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
This study is testing a new tablet, IMU-838, for people aged 18-55 with a type of multiple sclerosis (MS) called relapsing MS. It wants to see how well it works, if it's safe, and if people can tolerate it compared to a dummy tablet.
Multiple Sclerosis, Relapsing-RemittingEstonia - Active not recruitingPHASE3
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
This study is testing a new medicine, povetacicept, for adults with a kidney condition called IgA Nephropathy. We want to see if it can help reduce protein in the urine and protect kidney function compared to a dummy medicine.
Immunoglobulin A NephropathyEstonia - Active not recruitingNA
Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation
This study looks at different ways to care for unconscious patients after a sudden heart stop. It tests varying levels of calming medicine, body temperature control, and blood pressure targets to see what helps patients recover best and survive longer.
Cardiac Arrest With Successful ResuscitationHypoxia, BrainEstonia - RecruitingPHASE3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study looks at a long-term treatment called nerandomilast for people with pulmonary fibrosis. It's for those who've used it in a past study. We'll see how safe and effective it is over time, checking if it helps lung function and slows down the disease.
Idiopathic Pulmonary FibrosisProgressive Pulmonary FibrosisEstonia - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
This study looks at a new combination treatment for advanced lung cancer. It compares giving a well-known drug (pembrolizumab) with or without an additional drug (sacituzumab govitecan) to see which is better at slowing the cancer's growth and helping people live longer.
Carcinoma, Non-Small-Cell LungEstonia - Active not recruitingPHASE3
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
This study is looking at a new medicine called sonelokimab for people with psoriatic arthritis who haven't tried powerful biologic drugs before. It wants to see if sonelokimab is safe and helps improve their arthritis and skin.
Arthritis, PsoriaticEstonia - Active not recruitingPHASE3
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This study looks at new drug combinations for advanced liver cancer that has already been treated. It compares atezolizumab with lenvatinib or sorafenib against lenvatinib or sorafenib alone, to see if the combinations work better and are safe.
Unresectable Hepatocellular CarcinomaEstonia - RecruitingNA
LANDMARK Trial: a Randomised Controlled Trial of Myval THV
This study, called the LANDMARK Trial, is looking into how safe and effective a new heart valve called Myval THV is. It's compared to existing valves for people with a common heart condition called aortic valve stenosis. The goal is to see if it works just as well.
Aortic Valve StenosisEstonia - Recruiting
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
This study, called SPECTA, collects information and samples from cancer patients to help scientists better understand cancer. It aims to improve how we diagnose and treat different types of cancer in the future by looking at many different aspects of the disease.
All Tumor TypesEstonia - Active not recruitingPHASE3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
This study looks at the long-term safety and effectiveness of a medicine called ocrelizumab for people with Multiple Sclerosis (MS). It's for people already taking part in other ocrelizumab studies, to see how the treatment works over a longer time.
Multiple SclerosisEstonia - Active not recruitingPHASE3
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study looks at a new medicine called concizumab for people with haemophilia A or B without inhibitors. It aims to see how well it prevents bleeding and if it's safe. Participants will take the medicine daily, usually by injection under the skin, for up to 8 years.
Haemophilia A Without InhibitorsHaemophilia B Without InhibitorsEstonia - Enrolling by invitationNA
Optical Coherence Tomography in Acute Vessel Evaluation
This study compares two ways to help people having a heart attack: one uses standard X-rays, the other uses a special camera called OCT. We want to see if the OCT camera leads to better results for patients.
Ischemic Heart DiseaseIschemic Coronary Artery DiseaseACS (Acute Coronary Syndrome)Estonia - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
This study is testing a new medicine called empasiprubart for adults with a nerve condition called CIDP. It wants to see if the medicine is safe and helps people feel better. Participants will get the study medicine or a dummy medicine first, then everyone will get the study medicine.
Chronic Inflammatory Demyelinating PolyneuropathyCIDPChronic Inflammatory Demyelinating PolyradiculoneuropathyEstonia - Active not recruitingPHASE3
Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
This study is testing a new vaccine (PCV21) for healthy babies aged 2 to 4 months. It aims to see if it's safe and helps babies make germ-fighting antibodies against pneumococcal disease, comparing it to an existing vaccine alongside their routine immunisations.
Pneumococcal ImmunizationHealthy VolunteersEstonia - Enrolling by invitationPHASE3
Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency
This study is looking into the long-term safety of a treatment called Alpha-1 MP for people with a lung condition called Alpha-1 Antitrypsin Deficiency (AATD). It's for those who have already been part of a previous study and involves weekly drips of the medication.
Pulmonary Emphysema in Alpha-1 Antitrypsin DeficiencyEstonia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, multi-centric, placebo-controlled, participant and investigator-blinded study to evaluate the safety, tolerability and efficacy of TIN816 in adult patients at risk for acute kidney injury following cardiac surgery
This study is testing a new medicine, TIN816, for adults having heart surgery. It aims to see if TIN816 can protect kidneys from injury, which can sometimes happen after such operations. Researchers are checking how safe and effective the medicine is.
Acute kidney injuryEstonia - Recruiting
European Registry on the Management of Helicobacter Pylori Infection
This study is gathering information from doctors across Europe about how they treat H. pylori infection. It aims to understand current practices, check if guidelines are followed, and see what treatments work best to help improve care for patients with this common stomach infection.
H. Pylori InfectionEstonia - Active not recruitingPHASE2
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
This study looks at a new medicine called lutikizumab for adults with moderate to severe ulcerative colitis. It aims to see if it's safe and how well it works compared to a common treatment called adalimumab.
Ulcerative ColitisEstonia - RecruitingPHASE2
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
This study looks at whether a new medicine, BI 764198, can help adults and teenagers with certain kidney problems. It compares the new medicine to a dummy pill to see if it reduces protein in the urine and improves kidney health.
Proteinuric Kidney DiseasesEstonia - Recruiting
European Disease Registry on Retinopathy of Prematurity (ROP)
This study is gathering information about premature babies across Europe who need treatment for a serious eye condition called Retinopathy of Prematurity (ROP). It helps doctors understand how the condition affects babies and what treatments are used.
Retinopathy of PrematurityEstonia - Active not recruitingPHASE3
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
This study looks at how safe and effective two medicines, fingolimod and interferon beta-1a, are for young people aged 10-17 with multiple sclerosis (MS). It compares them to see which works best and is safest.
Multiple SclerosisEstonia - Active not recruiting
Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome
This study, SECRETO, looks into why younger adults have strokes when the cause isn't clear. It aims to find out what triggers these strokes, how people recover, and if genetics play a role, to help improve care for patients.
Brain InfarctionIschemic StrokeThrombosisForamen Ovale, PatentEstonia - Ongoing, recruitingTherapeutic use (Phase IV)
Vancomycin treatment in critically ill adults using model-informed precision dosing tool – prospective low-intervention clinical trial. (ProVanc)
This study looks at how well a new computer tool helps doctors give people with serious infections the right amount of vancomycin, an antibiotic. The goal is to make sure patients get the best dose to fight their infection effectively and safely.
Serious infections where according to the treating physician's decision treatment with intravenous vancomycin is needed.Estonia - Active not recruitingPHASE3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
This study looks at the long-term safety and effectiveness of a medicine called ofatumumab for people with relapsing MS. It also checks how well vaccines work in people taking this medicine, including those for flu, pneumonia, tetanus, and COVID-19.
Relapsing Multiple SclerosisEstonia - RecruitingPHASE3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
This study is looking at a new medicine called NBI-1065845 for people with depression. It's for those already taking antidepressants but still struggling. The main goal is to check its long-term safety and if people can take it alongside their usual treatment.
Major Depressive DisorderEstonia - RecruitingPHASE2
Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
This study looks into a new drug called Senicapoc for people with lung scarring diseases like pulmonary fibrosis. Researchers want to see if Senicapoc can stop the scarring from getting worse, compared to a dummy pill. It involves taking pills for 26 weeks and having check-ups.
Pulmonary Fibrosis, Interstitial Lung DiseaseIdiopathic Pulmonary FibrosisEstonia - Active not recruitingPHASE3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
This study looks at a new medicine called ziltivekimab for people with heart failure and inflammation. It aims to see if monthly injections of ziltivekimab can help, compared to a dummy medicine, over a few years.
Heart FailureEstonia - RecruitingPHASE3
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
This study, called ALLTogether, is for children and young adults aged 0-45 with acute lymphoblastic leukaemia (ALL). It aims to improve survival and reduce side effects by combining the best treatments from several countries and testing new approaches.
Leukemia, Acute LymphoblasticEstonia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
This study is testing a new medicine, orelabrutinib, for people with a type of multiple sclerosis called Primary Progressive MS (PPMS). We want to see if it can slow down the worsening of symptoms compared to a dummy pill (placebo).
Primary Progressive Multiple Sclerosis (PPMS)Estonia - Active not recruitingPHASE3
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
This study looks at two new medicines, ofatumumab and siponimod, for children and teenagers aged 10-17 with multiple sclerosis (MS). It compares them to a medicine called fingolimod to see if they are safe and work well.
Multiple Sclerosis (MS)Estonia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Randomized, placebo-controlled, double blind, multi-centre Phase IIb stuDy to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) – DHELIVER
This study, called DHELIVER, is testing a new treatment, HepaStem, for people with severe liver failure called ACLF. It aims to see if HepaStem can help people live longer and improve their liver health.
Estonia